TR200102769T2 - Testosteron undekanoat ve hint yağı ihtiva eden formülasyon - Google Patents

Testosteron undekanoat ve hint yağı ihtiva eden formülasyon

Info

Publication number
TR200102769T2
TR200102769T2 TR2001/02769T TR200102769T TR200102769T2 TR 200102769 T2 TR200102769 T2 TR 200102769T2 TR 2001/02769 T TR2001/02769 T TR 2001/02769T TR 200102769 T TR200102769 T TR 200102769T TR 200102769 T2 TR200102769 T2 TR 200102769T2
Authority
TR
Turkey
Prior art keywords
testosterone undecanoate
castor oil
liquid carrier
formulation containing
melt
Prior art date
Application number
TR2001/02769T
Other languages
English (en)
Inventor
Nijs De Henrik
Chandler Susan
Anne Perry Elizabeth
Joan Christine Ferdinando Josephine
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR200102769T2 publication Critical patent/TR200102769T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Açiklanmakta olan agiz yolu ile ilaç olarak verilmeye mahsus bir kapsülün biçimdeki eczacilik ile ilgili bir formülasyon olup, eczacilik ile ilgili olarak kabul edilebilir bir sivi tasiyici içinde çözülmüs olan testosteron undekanoati ihtiva etmektedir, özelligi de, sivi tasiyicinin agirlik ile en azindan % 50 Hint yagi ihtiva etmesidir. Androjen olarak testosteron undekanoatin seçilmesi ile birlesik olarak, sivi tasiyici olarak hint yaginin seçilmesi, TU'in 200 ila 250 mg/ml 'sini ihtiva edebilen bir eriyigi ortaya çikartmaktadir. Bu durum, testosteronun agiz yolu ile olmak üzere ilaç olarak verilebilir herhangi bir eriyigine yönelik olarak yeni bir erisme biçimi olmaktadir. Eriyik, ayni zamanda, lauroglikol gibi lipofilli bir yüzey aktif madde de ihtiva edebilmektedir.
TR2001/02769T 1999-04-01 2000-03-27 Testosteron undekanoat ve hint yağı ihtiva eden formülasyon TR200102769T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01

Publications (1)

Publication Number Publication Date
TR200102769T2 true TR200102769T2 (tr) 2002-05-21

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02769T TR200102769T2 (tr) 1999-04-01 2000-03-27 Testosteron undekanoat ve hint yağı ihtiva eden formülasyon

Country Status (26)

Country Link
EP (1) EP1189620B1 (tr)
JP (1) JP2002541111A (tr)
KR (1) KR100666016B1 (tr)
CN (1) CN1155385C (tr)
AT (1) ATE269708T1 (tr)
AU (1) AU768537B2 (tr)
BR (1) BR0009465A (tr)
CA (1) CA2366856C (tr)
CZ (1) CZ298573B6 (tr)
DE (1) DE60011771T2 (tr)
DK (1) DK1189620T3 (tr)
ES (1) ES2222199T3 (tr)
HU (1) HU229455B1 (tr)
ID (1) ID30481A (tr)
IL (2) IL145524A0 (tr)
MX (1) MXPA01009919A (tr)
NO (1) NO329420B1 (tr)
NZ (1) NZ514290A (tr)
PL (1) PL195163B1 (tr)
PT (1) PT1189620E (tr)
RU (1) RU2246296C2 (tr)
SK (1) SK286071B6 (tr)
TR (1) TR200102769T2 (tr)
TW (1) TWI280124B (tr)
WO (1) WO2000059512A1 (tr)
ZA (1) ZA200107781B (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
CA2604943C (en) * 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2008040488A1 (en) 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AU2010351080B2 (en) * 2010-04-12 2014-08-28 Besins Healthcare Luxembourg S.A.R.L. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
UA114705C2 (uk) * 2011-01-26 2017-07-25 Аллерган, Інк. Андрогенна композиція для лікування офтальмологічного захворювання
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AU2015276321B2 (en) 2014-06-17 2019-10-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033611A1 (en) * 2014-08-29 2016-03-03 Lipocine Inc. (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) * 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
ES2222199T3 (es) 2005-02-01
IL145524A0 (en) 2002-06-30
CN1346274A (zh) 2002-04-24
NO20014718D0 (no) 2001-09-28
HUP0200453A2 (hu) 2002-07-29
HUP0200453A3 (en) 2003-06-30
BR0009465A (pt) 2002-01-08
DE60011771T2 (de) 2004-11-04
AU768537B2 (en) 2003-12-18
PL195163B1 (pl) 2007-08-31
RU2246296C2 (ru) 2005-02-20
PL351259A1 (en) 2003-04-07
AU4111100A (en) 2000-10-23
EP1189620B1 (en) 2004-06-23
CA2366856A1 (en) 2000-10-12
PT1189620E (pt) 2004-10-29
IL145524A (en) 2006-12-31
JP2002541111A (ja) 2002-12-03
NO20014718L (no) 2001-09-28
HK1043544A1 (en) 2002-09-20
KR20010108435A (ko) 2001-12-07
NZ514290A (en) 2003-08-29
NO329420B1 (no) 2010-10-18
CA2366856C (en) 2006-05-16
SK13722001A3 (sk) 2002-02-05
CZ20013507A3 (cs) 2002-03-13
EP1189620A1 (en) 2002-03-27
ID30481A (id) 2001-12-13
DK1189620T3 (da) 2004-08-16
HU229455B1 (en) 2013-12-30
ZA200107781B (en) 2002-12-20
ATE269708T1 (de) 2004-07-15
CZ298573B6 (cs) 2007-11-14
SK286071B6 (sk) 2008-02-05
KR100666016B1 (ko) 2007-01-10
TWI280124B (en) 2007-05-01
MXPA01009919A (es) 2002-04-24
WO2000059512A1 (en) 2000-10-12
CN1155385C (zh) 2004-06-30
DE60011771D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
TR200102769T2 (tr) Testosteron undekanoat ve hint yağı ihtiva eden formülasyon
GB9907715D0 (en) Pharmaceutical compositions
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
ES2210554T3 (es) Composicion farmaceutica que comprende coenzima q 10.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
WO2017196148A1 (en) Composite formulation of dutasteride and tadalafil comprising glycerol fatty acid ester derivative or propylene glycol fatty acid ester derivative and oral capsule formulation comprising the same
DE60139907D1 (de) Pharmazeutische Zubereitung enthaltend Drospirenon
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
RU2001101892A (ru) Производное тестостерона
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
WO2010044093A1 (en) Formulations containing rifaximin
ATE156119T1 (de) 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
WO1999008684A2 (en) Solutions containing azasteroids
PA8498901A1 (es) Sal polimorfica
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
NO20002590L (no) Formuleringer omfattende oppløst paroxetin
EE03954B1 (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvormi valmistamise meetod
AR005569A1 (es) Un metodo para inducir la muerte de celulas neoplasicas mediante derivados de la piperazina
BR0014687A (pt) Compostos de taxano pentacìclico
Li et al. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration
ATE260893T1 (de) S-nitroso- und s-nitro-n-acyl-l-cystein-ester- derivate als pharmakologische wirkstoffe und diese verbindungen enthaltende arzneimittel